International Journal of Medicinal Mushrooms

ISSN for PRINT: 1521-9437

For Online Access

Best Paper Award Selection - Editorial Board Site

2003, Volume5

Issue 3

112 pages

DOI: 10.1615/InterJMedicMush.v5.i3

Issue price - $128.00

John E. Smith
Department of Bioscience&Biotechnology University of Strathclyde Royal College, Building 204 George Street Glasglow, Scotland, UK; and Mycobiotech Pte Ltd., Singapore Science Part, Singapore

Richard Sullivan
Head of Clinical Programmes, Cancer Research UK, PO Box 123, Lincoln’s Inn Field, London WC2A 3PX, UK

Neil J. Rowan
Department of Bioscience and Biotechnology, University of Strathclyde, 204 George Street, Glasgow G1 1XW, Scotland, UK

Mushroom-derived polysaccharides are now considered to be compounds that are able to modulate animal and human immune responses and to inhibit certain tumor growths. This review sets out the current information on the use of various mushroom polysaccharides in cancer treatments. Many human cancer cell lines have been studied, and in some cases direct cytotoxic effects have been demonstrated. Several mushroom polysaccharide compounds have proceeded through Phases I, II, and III clinical trials and are used extensively and successfully in Asia to treat various cancers. It is considered that such proprietary mushroom compounds will be seen mainly as complementary or adjunctive therapies to be used together with mainstream care therapies.

DOI: 10.1615/InterJMedicMush.v5.i3.10 Download article, 18 pages

Article price - $35.00

  Next article >>